LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models

Area of Science:

• Neuroscience
• Genetics
• Pathology

Background:

• Mutations in leucine-rich repeat kinase 2 (LRRK2) cause autosomal dominant Parkinson's disease (PD).
• Alpha-synuclein and tau pathologies are prevalent in LRRK2-PD, indicating shared mechanisms with idiopathic PD.
• Protein aggregates are a common feature in both LRRK2-PD and idiopathic PD.

Purpose of the Study:

• To review evidence linking LRRK2 mutations to protein aggregation in animal models of Parkinson's disease.
• To explore the role of LRRK2 in the pathogenesis of protein aggregation and neurodegeneration in PD.
• To understand if targeting LRRK2 can modify protein aggregate accumulation, transmission, or toxicity.

Main Methods:

• Review of existing literature on LRRK2, protein aggregation, and Parkinson's disease in animal models.
• Analysis of studies investigating the interplay between LRRK2 mutations and alpha-synuclein/tau pathology.
• Synthesis of findings from animal models to elucidate LRRK2-dependent neurodegeneration mechanisms.

Main Results:

• Animal models provide insights into the potential interaction between LRRK2 and protein aggregation.
• Evidence suggests LRRK2 may influence the formation and spread of protein aggregates.
• The precise mechanisms by which LRRK2 mutations drive PD pathogenesis and protein aggregation remain under investigation.

Conclusions:

• LRRK2 mutations are implicated in Parkinson's disease pathogenesis through mechanisms potentially involving protein aggregation.
• Animal models are crucial for dissecting the complex relationship between LRRK2 and proteinopathies.
• Further research is needed to clarify the role of LRRK2 in PD and its potential as a therapeutic target for modifying protein aggregates.